På dette tidspunkt var det CHMPs opfattelse, at Alpheon ikke kunne anses for at være et biosimilært lægemiddel til referencelægemidlet Roferon- A.
At this point in time, the CHMP was of the opinion that Alpheon could not be considered as a biosimilar medicine of Roferon-A, the reference medicinal product.